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Our objective was to determine the relationship between polyphar-
macy (treatment  with  prescription drugs  from 6 or  more drug
classes concurrently) and health-related quality of life (HRQoL)
among US adults with arthritis.
Methods
We conducted a retrospective cohort study that used 2-year longit-
udinal data from the Medical Expenditure Panel Survey to ana-
lyze a cohort of 6,132 adults aged over 21 years with arthritis.
Measures of HRQoL were the summary scores from the mental
component summary (MCS) and physical component summary
(PCS) of the 12-item short-form health survey. Unadjusted and ad-
justed regression models were used to evaluate the association
between polypharmacy and HRQoL measures. We used SAS, ver-
sion 9.4, (SAS Institute Inc) to conduct all analyses.
Results
In unadjusted analyses, adults with arthritis taking prescription
drugs from 6 or more drug classes concurrently had significantly
lower MCS and PCS scores (β, −3.11, P < .001 and β, −10.26, P <
.001, respectively) than adults taking prescription drugs from few-
er than 6. After controlling for the demographic characteristics,
number of mental and physical chronic conditions, and baseline
MCS and PCS scores, adults taking prescription drugs from 6 or
more drug classes concurrently had significantly lower PCS scores
(β, −1.68, P < .001), than those taking prescription drugs from
fewer than 6. However, no significant difference in MCS scores
was found between adults  taking prescription drugs from 6 or
more drug classes concurrently and those taking prescription drugs
from fewer than 6 (β, −0.27, P = .46).
Conclusion
Polypharmacy is significantly associated with lower PCS scores
among adults with arthritis. Because polypharmacy can lead to
drug–drug and drug–disease interactions, health care providers
need to consider the risk and adopt a cautious approach in pre-
scribing  multiple  drugs  to  manage  chronic  conditions  and  in
choosing therapies to improve HRQoL among adults with arthritis.
Introduction
Arthritis is one of the most prevalent diseases among adults in the
United States (1–3) and is the leading cause of adult disability
(3,4). Nearly 52.5 million adults reported having some form of
arthritis from 2010 through 2012 (2). Arthritis has a negative im-
pact on health-related quality of life (HRQoL) (5–8). Adults with
arthritis  have worse HRQoL than those without arthritis  (7,8).
Arthritis  is  a  greater  detriment to HRQoL than other  common
chronic conditions, such as lung disease, congestive heart failure,
diabetes, hypertension, and ischemic heart disease (9). Results
from previous clinical trials indicated that pharmacologic treat-
ment of arthritis improved HRQoL among adults with arthritis
(5,10,11).
Arthritis-related pharmacotherapy can include multiple drug regi-
mens, including analgesics, anti-inflammatory drugs, corticoster-
oids, disease-modifying antirheumatic drugs, or biological ther-
apies (12,13). Adults with arthritis may have multiple co-existing
conditions (2,14) that could be treated with medication. For ex-
ample, if a woman with osteoarthritis has 4 other chronic condi-
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tions (eg, diabetes, hypertension, chronic obstructive pulmonary
disease, osteoporosis), she could be prescribed 12 separate medic-
ations based on clinical guidelines (15). Some adults with arthritis
may be on multiple arthritis-related medications, and if co-exist-
ing conditions are also treated with drugs, these adults may be
treated with polypharmacy (treatment with prescription drugs from
6 or more drug classes concurrently).
High rates of polypharmacy have been documented among adults
with arthritis (12,13,16). In addition, polypharmacy is often asso-
ciated  with  low  HRQoL  (17–19).  Although  the  association
between arthritis and polypharmacy was documented (12,13,16),
no study to date has examined the effect of polypharmacy on HR-
QoL among US adults with arthritis. Therefore, the objective of
our study was to assess the relationship between polypharmacy
and HRQoL measures among US adults with arthritis.
Methods
We conducted a longitudinal retrospective cohort study with a
baseline year and follow-up year by using data from 2 longitudin-
al  panels  of  the  Medical  Expenditure  Panel  Survey  (MEPS).
MEPS is an annual household survey of noninstitutionalized civil-
ians (20). Interviews were conducted 5 times over the course of 2
years to minimize recall bias, providing longitudinal data (20).
Computer-assisted personal interviewing technology was used to
collect  information on each household member.  We combined
data  from  2  panels,  panel  15  (2010–2011)  and  panel  16
(2011–2012) to increase sample size.
We used information provided by the households to identify med-
ical conditions, prescription drugs used, HRQoL measures, health
status, demographic and socioeconomic characteristics, employ-
ment status, and access to care (20). Chronic conditions were eli-
cited by asking respondents to enumerate the 1) conditions in the
MEPS priority list; 2) conditions leading to emergency, outpatient,
inpatient, and other hospital visits; 3) conditions causing disabil-
ity; and 4) conditions that bothered the respondents during a refer-
ence period (20). The study cohort consisted of adults aged over
21 years who were alive and had arthritis during the baseline year.
Arthritis was identified from household or medical conditions files
of MEPS. We identified adults with arthritis as those who repor-
ted having arthritis in the household file or were linked to Interna-
tional Classification of Diseases, Ninth Revision (ICD-9) codes
201, 202, 203, or 204 in the medical conditions file.
Measures
Outcome was assessed by HRQoL by using the 12-item short form
(SF-12) health survey (21). The short form measures 8 domains:
general health, vitality, physical functioning, role–physical (limita-
tions in work and daily activities because of physical problems),
bodily pain,  social  functioning,  role–emotional  (limitations in
work and daily activities because of emotional problems), and
mental  health  (11,22).  MEPS provides  information on mental
component summary (MCS) scores and physical component sum-
mary (PCS) scores. We used MCS and PCS scores to represent
mental and physical health components of HRQoL. MCS and PCS
scores range from 0 to 100, with higher scores representing better
self-reported health and better HRQoL (11,22). The mean score of
the general US population is 50 (22). The established MCS norms
for the national sample of people with osteoarthritis and rheumat-
oid arthritis are 47.53 and 47.15, respectively, whereas the estab-
lished PCS norm for people with osteoarthritis is 38.91 and for
those with rheumatoid arthritis is 40.57 (22).
Polypharmacy was the key explanatory variable assessed. There is
no consensus definition of polypharmacy; however, taking pre-
scription drugs from 6 or more drug classes concurrently was a
widely used definition in previous studies (23). Thus, we categor-
ized the adults in our cohort by whether, during the baseline year,
they were taking prescription drugs from 6 or more drug classes
concurrently or taking prescription drugs from fewer than 6 drug
classes  concurrently.  The MEPS prescription medications  file
provides  information  on  therapeutic  classes  of  medications
through  linkage  with  the  Multum  Lexicon  database  (http://
www.multum.com/Lexicon.htm) (24). We used the unique thera-
peutic class codes from this database to identify the maximum
number of classes of medications taken by people in the baseline
year.
Other explanatory variables measured during the baseline year
were sex (female, male); age (22–39 y, 40–49 y, 50–64 y, 65–74
y, ≥75 y); race/ethnicity (white, African American, Latino, or oth-
er); marital status (married, separated/divorced, widowed, or nev-
er married); poverty status based on the household’s annual in-
come as a percentage of the federal poverty line (poor, <100%;
near poor, 100% to <200%; middle income, 200% to <400%; high
income, ≥400%); health insurance coverage (private, public, unin-
sured); prescription drug coverage (yes or no); the presence of oth-
er  co-occurring physical  conditions  (asthma,  diabetes,  cancer,
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gastroesophageal reflux disease, heart disease, hypertension, os-
teoporosis, thyroid, chronic obstructive pulmonary disease), and
mental conditions (depression, anxiety); baseline HRQoL meas-
ures; smoking status (current smoker or not current smoker; body
mass index (BMI) (kg/m2) (underweight/normal [≤24.9], over-
weight [25.0−29.9], or obese [≥30.0]); and geographic area of res-
idence (metropolitan or rural).
We controlled for baseline PCS in the models because a study by
Fortin and colleagues suggested that lower PCS scores were asso-
ciated with severity of illness for many of the chronic conditions
they examined from a list of 14 anatomical domains (eg, cardiac,
respiratory, renal, metabolic) (25).
Statistical analysis
We used χ2 to examine the associations between polypharmacy
and other explanatory variables in the bivariate analysis. The rela-
tionship between polypharmacy and HRQoL measures (MCS and
PCS) was assessed by using t tests.
Because of the nature of the outcome, multivariable ordinary least
squares (OLS) regressions were used to examine the association
between polypharmacy and follow-up HRQoL measures (MCS
and PCS) separately.
We constructed unadjusted and adjusted models with these as ex-
planatory variables: number of co-existing chronic physical and
mental conditions, baseline MCS and PCS scores, sex, age, race/
ethnicity, marital status, poverty status, health insurance coverage,
prescription drug coverage, BMI, smoking status, and geographic
area of residence. In all models, the reference group was “no poly-
pharmacy.”
All analyses accounted for the complex survey design of MEPS,
and statistical testing was carried out with survey procedures in
SAS, version 9.4 (SAS Institute Inc). Because of multiple compar-
isons, we reported all P values, and we considered variables with a
P value of less than .05 to be significant.
Results
In  the  combined  MEPS panels,  6,132  adults  had  data  for  the
baseline year and were alive during the follow-up year. We found
polypharmacy among 28% of our cohort; nearly 70% of our co-
hort had at least 1 additional chronic physical condition. Adults
with 5 or more chronic physical conditions had the highest rate of
polypharmacy (89.1%). Those with 3 or 4 chronic physical condi-
tions had a significantly higher rate of polypharmacy than those
with 1 or 2 chronic physical conditions (63.2% vs 24.3%). Among
adults with depression or anxiety, 45.3% took 6 or more prescrip-
tion medications compared with 25.5% of adults without depres-
sion or anxiety. Adults with prescription drug coverage had signi-
ficantly higher rates of polypharmacy than those without prescrip-
tion drug coverage (35.9% vs 1.7%). Significant associations were
found between polypharmacy and all the explanatory variables in-
cluded in the study (Table 1).
HRQoL measures by polypharmacy
The mean MCS scores for the cohort during the baseline year and
follow-up years were 49.35 (SE, 0.17) and 49.57 (SE, 0.18), re-
spectively.  The  mean  PCS  scores  for  the  cohort  during  the
baseline and follow-up years were 42.61 (SE, 0.19) and 42.39 (SE,
0.19), respectively (Table 2). The mean MCS and PCS scores by
polypharmacy during the baseline and follow-up years are listed in
Table 2.
 Table 3 displays parameter estimates of polypharmacy from each
OLS regression using MCS and PCS scores as outcomes. In the
unadjusted model, adults taking prescription drugs from 6 or more
drug classes  concurrently had significantly lower MCS scores (β,
−3.11; P < .001) and PCS scores (β, −10.26; P < .001) than those
taking prescription drugs from fewer than 6.
After  controlling  for  sex,  age,  race/ethnicity,  marital  status,
poverty status, health insurance coverage, prescription drug cover-
age,  number  of  mental  and  physical  health  conditions,  BMI,
smoking status, geographic area of residence, and baseline MCS
and PCS scores, adults taking prescription drugs from 6 or more
drug classes concurrently had significantly lower PCS scores (β,
−1.68; P < .001) than those taking prescription drugs from fewer
than 6. However, no significant difference in MCS scores was
found between adults taking prescription drugs from 6 or more
drug classes concurrently and those taking prescription drugs from
fewer than 6 (β, −0.27, P = .46).
Sensitivity analyses
We conducted 2 sensitivity analyses that used different definitions
of polypharmacy to test the robustness of the results. In the first
sensitivity analysis, we defined polypharmacy as using prescrip-
tion drugs from 4 or more drug classes concurrently. In the second
sensitivity analysis, we defined polypharmacy as using drugs from
5 or more drug classes. In both analyses, the negative associations
between polypharmacy and PCS scores remained significant and
consistent with the primary analyses.
With polypharmacy defined as taking prescription drugs from 4 or
more drug classes concurrently, the unadjusted analyses indicated
negative associations between polypharmacy and MCS (β, −2.72;
P < .001) and PCS (β, −9.50; P < .001) scores. In the adjusted
model,  adults  taking  prescription  drugs  from 4  or  more  drug
classes concurrently had significantly lower PCS scores than those
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taking prescription drugs from fewer drug classes (β, −1.71; P <
.001). However, we found no difference in MCS scores between
adults taking prescription drugs from 4 or more drug classes con-
currently and those taking prescription drugs from fewer drug
classes (β, −0.31; P = .37).
With polypharmacy defined as taking prescription drugs from 5 or
more drug classes concurrently, unadjusted models indicated neg-
ative associations between polypharmacy and MCS (β, −3.00; P <
.001) and PCS scores (β, −9.85; P < .001). In the adjusted model,
adults taking prescription drugs from 5 or more drug classes con-
currently had significantly lower PCS scores than those taking pre-
scription drugs from fewer drug classes (β, −1.87; P < .001). We
found no difference in MCS scores (β, −0.31; P = .39).
Discussion
Our study examined the relationship between polypharmacy and
HRQoL among adults  with arthritis.  Among our cohort  of  US
adults with arthritis, 28% were found to be taking prescription
drugs from 6 or more drug classes concurrently. The average PCS
scores for these adults were below the established PCS norms for
people with osteoarthritis and rheumatoid arthritis, suggesting that
adults in our cohort had poorer health than the general US popula-
tion with osteoarthritis or rheumatoid arthritis. We also found that
more adults taking prescription drugs from 6 or more drug classes
concurrently had 3 or more chronic physical conditions compared
with  those  taking  prescription  drugs  from fewer  drug classes.
After controlling for other explanatory variables, adults taking pre-
scription drugs from 6 or more drug classes concurrently had sig-
nificantly lower PCS scores than those taking prescription drugs
from fewer drug classes.
Our results suggest that polypharmacy is negatively associated
with PCS scores among adults with arthritis. Our findings are con-
sistent with those of previous studies showing that polypharmacy
is associated with low PCS scores among older American Indians
(18), rural elderly (19), and male veterans (17).
Nearly 70% of the adults  in our cohort  had 1 or more chronic
physical conditions in addition to arthritis. The management of
arthritis often requires multiple prescription medications, includ-
ing analgesics, anti-inflammatory drugs, corticosteroids, disease-
modifying antirheumatic drugs, or biological therapies (12,13); co-
existing conditions may need to be treated with drugs, placing
adults with arthritis at high risk for polypharmacy. Polypharmacy
is associated with drug–drug and drug–disease interactions that
may lead to development of new diseases or worsen control of ex-
isting diseases. Therefore, health care providers need to weigh the
harms and benefits before prescribing multiple drugs for the man-
agement of arthritis and other co-occurring conditions. In addition,
further investigation of the impact of the different drug classes on
the PCS measure is needed. Identifying the drug classes that are
associated with lower PCS scores was beyond the scope of this
study.
In the adjusted analyses,  we found no differences in the MCS
scores between adults taking prescription drugs from 6 or more
drug classes concurrently and those taking prescription drugs from
fewer drug classes. This is consistent with the results of a previ-
ous study showing that polypharmacy is not associated with MCS
scores among older American Indians (18). Nevertheless, the aver-
age MCS scores for adults in our study cohort were above the es-
tablished MCS norms for people with osteoarthritis and rheumat-
oid arthritis (22).
To the best of our knowledge, this is the first study that assesses
the relationship between polypharmacy and HRQoL measures
among adults with arthritis by using a nationally representative
data set and well-established and validated measures of HRQoL.
We controlled for a comprehensive list of factors that may affect
HRQoL. Availability of information on prescription drug classes
enabled us to measure polypharmacy. However, this study had
limitations. First, information on all the variables was based on
self-reported data, which increases the risk for recall bias. Second,
we could not control for the severity of arthritis in the baseline
year. Third, MEPS does not provide information on nonprescrip-
tion drugs, such as analgesics and anti-inflammatories. Finally, we
did not explicitly control for arthritis-related treatment that may
affect HRQoL.
Polypharmacy is significantly associated with lower PCS scores
among adults with arthritis. Further research is required to identi-
fy the drug classes associated with low PCS scores. Because poly-
pharmacy can lead to drug–drug and drug–disease interactions,
health care providers should assess risk and adopt a cautious ap-
proach in prescribing multiple drugs to manage chronic condi-
tions and should choose therapies that improve HRQoL among
adults with arthritis.
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Tables
Table 1. Characteristics of the Study Sample of Adults with Arthritis (N = 6,132), by Polypharmacy, Medical Expenditure Panel Survey (MEPS), Panels 2010–2012a
Characteristic No Polypharmacy, n (Weighted %) Polypharmacy, n (Weighted %) P Valueb
All 4,436 (71.8) 1,696 (28.2) —
Osteoarthritis
Yes 1,179 (66.0) 573 (34.1)
<.001
No 3,257 (74.5) 1,123 (25.5)
Rheumatoid arthritis
Yes 535 (62.6) 299 (37.4)
<.001
No 3,901 (73.0) 1,397 (27.0)
Other forms of arthritisc
Yes 2,722 (77.0) 824 (23.0)
<.001
No 1,714 (65.1) 872 (35.0)
Sex
Female 2,608 (69.3) 1,118 (30.7)
<.001
Male 1,828 (75.2) 578 (24.8)
Age
22–39 773 (92.9) 57 (7.1)
<.001
40–49 843 (84.5) 150 (15.5)
50–64 1,583 (71.4) 643 (28.6)
65–74 726 (60.6) 447 (39.4)
≥75 511 (55.7) 399 (44.4)
Race/ethnicity
White 2,488 (70.7) 1,043 (29.3)
.004
African American 911 (72.8) 370 (27.2)
Latino 749 (77.5) 196 (22.5)
Other 288 (75.2) 87 (24.8)
Marital status
Married 2,401 (74.3) 773 (25.7)
<.001
Separated/divorced 909 (70.4) 394 (29.6)
Widowed 433 (54.6) 365 (45.4)
Never married 693 (79.2) 164 (20.8)
Abbreviation: —, not applicable.
a Polypharmacy was defined as taking prescription drugs from 6 or more drug classes concurrently. Data were combined from 2 MEPS panels, 2010–2011 and
2011–2012, for adults aged over 21 years who reported having arthritis during the baseline year and were alive throughout the baseline and following year.
b P values were derived from χ2 tests between polypharmacy groups and explanatory variables.
c Infective arthritis and osteomyelitis (International Classification of Diseases, Ninth Revision, [ICD-9] code 201), other nontraumatic joint disorders (ICD-9 code
204), or reported unspecified arthritis.
d Poverty status was based on annual family income in relation to the federal poverty line. Participants were divided into 4 groups on the basis of their income’s
percentage of the federal poverty line: poor (less than 100%), near poor (100% to <200%), middle income (200% to <400%), and high income (≥400%)
e Asthma, diabetes, cancer, gastroesophageal reflux disease, heart disease, hypertension, osteoporosis, thyroid disease, and chronic obstructive pulmonary dis-
ease.
f Anxiety or depression.
(continued on next page)
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(continued)
Table 1. Characteristics of the Study Sample of Adults with Arthritis (N = 6,132), by Polypharmacy, Medical Expenditure Panel Survey (MEPS), Panels 2010–2012a
Characteristic No Polypharmacy, n (Weighted %) Polypharmacy, n (Weighted %) P Valueb
Poverty statusd
Poor 834 (67.0) 397 (33.0)
.001
Near poor 988 (68.4) 438 (31.6)
Middle income 1,315 (73.3) 438 (26.7)
High income 1,299 (74.3) 423 (25.7)
Health insurance coverage
Private 2,561 (74.4) 845 (25.6)
<.001Public 1,240 (59.4) 791 (40.6)
Uninsured 635 (89.6) 60 (10.4)
Prescription drug coverage
Yes 3,020 (64.1) 1,672 (35.9)
<.001
No 1,416 (98.3) 24 (1.7)
Chronic physical conditions,e no.
None 1,730 (96.5) 55 (3.5)
<.001
1–2 2,215 (75.7) 682 (24.3)
3–4 466 (36.8) 764 (63.2)
≥5 25 (10.9) 195 (89.1)
Chronic mental conditions,f no.
None 3,968 (74.5) 1,334 (25.5)
<.001
≥1 468 (54.7) 362 (45.3)
Body mass index (kg/m2)
Underweight/normal (<24.9) 1,249 (79.7) 307 (20.3)
<.001Overweight (25.0–29.9) 1,526 (74.5) 494 (25.5)
Obese (≥30.0) 1,577 (64.0) 860 (36.0)
Smoking status
Current smoker 925 (75.4) 290 (24.6)
.03
All others 3,440 (71.0) 1,369 (29.0)
Geographic area of residence
Urban 3,745 (72.9) 1,342 (27.1)
.002
Rural 691 (66.7) 354 (33.3)
Abbreviation: —, not applicable.
a Polypharmacy was defined as taking prescription drugs from 6 or more drug classes concurrently. Data were combined from 2 MEPS panels, 2010–2011 and
2011–2012, for adults aged over 21 years who reported having arthritis during the baseline year and were alive throughout the baseline and following year.
b P values were derived from χ2 tests between polypharmacy groups and explanatory variables.
c Infective arthritis and osteomyelitis (International Classification of Diseases, Ninth Revision, [ICD-9] code 201), other nontraumatic joint disorders (ICD-9 code
204), or reported unspecified arthritis.
d Poverty status was based on annual family income in relation to the federal poverty line. Participants were divided into 4 groups on the basis of their income’s
percentage of the federal poverty line: poor (less than 100%), near poor (100% to <200%), middle income (200% to <400%), and high income (≥400%)
e Asthma, diabetes, cancer, gastroesophageal reflux disease, heart disease, hypertension, osteoporosis, thyroid disease, and chronic obstructive pulmonary dis-
ease.
f Anxiety or depression.
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Table 2. Health-Related Quality of Life Measures During Baseline and Follow-up Year, by Polypharmacya, Adults (N = 6,132) With Arthritis, Medical Expenditure Pan-
el Survey, Panels 2010–2012b
Category Component Summary Score, Mean (SE) P Value
Mental, baseline year
All 49.35 (0.17) —
Polypharmacy 47.27 (0.30)
<.001
No polypharmacy 50.20 (0.22)
Mental, follow-up year
All 49.57 (0.18) —
Polypharmacy 47.43 (0.32)
<.001
No polypharmacy 50.44 (0.22)
Physical, baseline year
All 42.61 (0.19) —
Polypharmacy 35.32 (0.37)
<.001
No polypharmacy 45.58 (0.19)
Physical, follow-up year
All 42.39 (0.19) —
Polypharmacy 35.13 (0.37)
<.001
No polypharmacy 45.34 (0.20)
Abbreviation —, not applicable.
a Polypharmacy was defined as taking prescription drugs from 6 or more drug classes concurrently. Number in the polypharmacy group was 1,696; for the no poly-
pharmacy group, the number was 4,436.
b Adults aged over 21 years who reported having arthritis during the baseline year and were alive throughout the baseline and following year.
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Table 3. Parameter Estimates of Polypharmacya From Ordinary Least Squares Regression Outcomes Relative to Mental Component Summary (MCS) Score and
Physical Component Summary (PCS) Score, Adults with Arthritis (N = 6,132)b, Medical Expenditure Panel Survey, Panels 2010–2012
Explanatory Variable
MCS PCS
β (SE) P Value β (SE) P Value
Unadjusted model
Polypharmacy −3.11 (0.41) <.001 −10.26 (0.42) <.001
No polypharmacy Reference Reference
Adjusted model
Polypharmacy −0.27 (0.37) .46 −1.68 (0.38) <.001
No polypharmacy Reference Reference
Abbreviation: SE, standard error.
a Polypharmacy was defined as taking prescription drugs from 6 or more drug classes concurrently.
b Adults aged over 21 years who reported having arthritis during the baseline year and were alive throughout the baseline and following year. Adjusted model in-
cluded sex, age, race/ethnicity, marital status, poverty status, health insurance coverage, prescription drug coverage, number of mental and physical health condi-
tions, body mass index (kg/m2), smoking status, geographic area of residence, and baseline MCS and PCS scores.
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